Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
892,606
-
Share change
-
-1,593
-
Total reported value
-
$6,646,000
-
Price per share
-
$7.45
-
Number of holders
-
13
-
Value change
-
-$472,233
-
Number of buys
-
6
-
Number of sells
-
3
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q3 2021
As of 30 Sep 2021,
Gain Therapeutics, Inc. - COM (GANX) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
892,606 shares.
The largest 10 holders included
GREENLIGHT CAPITAL INC, Telemetry Investments, L.L.C., CM Management, LLC, PRELUDE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Indie Asset Partners, LLC, Veritable, L.P., BlackRock Inc., UBS Group AG, and Banque Cantonale Vaudoise.
This page lists
13
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.